From: Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Disease type | Specimen count | Median mutations/Mb | Percentage cases with >20 mutations/Mb (95% CI) |
---|---|---|---|
Skin basal cell carcinoma | 92 | 47.3 | 70.7 (60.7–79) |
Skin squamous cell carcinoma (SCC) | 266 | 45.2 | 67.3 (61.4–72.7) |
Skin melanoma | 879 | 14.4 | 39.7 (36.4–42.9) |
Skin merkel cell carcinoma | 206 | 4.3 | 37.9 (31.5–44.7) |
Unknown primary melanoma | 1324 | 12.6 | 37.6 (35–40.2) |
Head and neck melanoma | 59 | 6.3 | 25.4 (14.7–36) |
Lung large cell carcinoma | 74 | 12.2 | 24.3 (14.9–33.7) |
Unknown primary squamous cell carcinoma (SCC) | 606 | 7.6 | 21.6 (18.4–24.9) |
Lung large cell neuroendocrine carcinoma | 288 | 9.9 | 19.8 (15.6–24.8) |
Lung sarcomatoid carcinoma | 130 | 7.2 | 19.2 (12.7–26) |
Stomach adenocarcinoma intestinal type | 58 | 5.0 | 19 (10.9–30.9) |
Uterus endometrial adenocarcinoma endometrioid | 459 | 4.5 | 18.5 (15–22.1) |
Lymph node lymphoma diffuse large B cell | 348 | 10.0 | 18.4 (14.7–22.8) |
Lung non-small cell lung carcinoma (NOS) | 2636 | 8.1 | 17 (15.6–18.5) |
Unknown primary sarcomatoid carcinoma | 64 | 5.4 | 15.6 (7.6–24.6) |
Unknown primary malignant neoplasm (NOS) | 491 | 3.8 | 14.9 (12–18.3) |
Uterus endometrial adenocarcinoma (NOS) | 743 | 4.5 | 14.7 (12.3–17.4) |
Bladder carcinoma (NOS) | 77 | 8.1 | 14.3 (8.2–23.8) |
Unknown primary urothelial carcinoma | 188 | 7.2 | 13.8 (9.2–18.9) |
Soft tissue angiosarcoma | 157 | 3.3 | 13.4 (8.9–19.6) |
Lung adenocarcinoma | 11855 | 6.3 | 12.3 (11.7–12.9) |
Lung adenosquamous carcinoma | 154 | 5.4 | 12.3 (7.5–17.7) |
Skin adnexal carcinoma | 74 | 3.6 | 12.2 (6.5–21.5) |
Bladder urothelial (transitional cell) carcinoma | 1218 | 7.2 | 11.9 (10.1–13.8) |
Lymph node lymphoma B-cell (NOS) | 88 | 6.3 | 11.4 (6.3–19.7) |
Lung squamous cell carcinoma (SCC) | 2102 | 9.0 | 11.3 (10–12.7) |
Unknown primary carcinoma (NOS) | 1405 | 4.5 | 10.7 (9.2–12.4) |
Head and neck squamous cell carcinoma (HNSCC) | 1184 | 5.0 | 10.1 (8.5–11.9) |
Lung small cell undifferentiated carcinoma | 913 | 9.9 | 9 (7.3–11) |
Nasopharynx and paranasal sinuses squamous cell Carcinoma (SCC) | 67 | 4.5 | 9 (4.2–18.2) |
Ovary endometrioid adenocarcinoma | 105 | 3.6 | 8.6 (4.6–15.5) |
Unknown primary undifferentiated small cell carcinoma | 117 | 6.3 | 8.5 (4.1–14) |
Brain oligodendroglioma | 321 | 2.7 | 8.4 (5.6–11.6) |
Small intestine adenocarcinoma | 277 | 4.5 | 8.3 (5.3–11.7) |
Soft tissue malignant peripheral nerve sheath tumor (MPNST) | 134 | 2.5 | 8.2 (4.1–13.2) |
Soft tissue sarcoma undifferentiated | 260 | 2.5 | 8.1 (5.3–12) |
Uterus endometrial adenocarcinoma clear cell | 62 | 3.6 | 8.1 (3.5–17.5) |
Prostate undifferentiated carcinoma | 91 | 3.6 | 7.7 (3.8–15) |
Salivary gland mucoepidermoid carcinoma | 55 | 2.7 | 7.3 (2.9–17.3) |
Unknown primary adenocarcinoma | 2751 | 3.6 | 6.9 (6–7.9) |
Ureter urothelial carcinoma | 88 | 5.4 | 6.8 (2.5–12.6) |
Cervix squamous cell carcinoma (SCC) | 284 | 5.4 | 6.7 (4.3–10.2) |
Penis squamous cell carcinoma (SCC) | 60 | 4.5 | 6.7 (2.6–15.9) |
salivary gland carcinoma (NOS) | 160 | 3.6 | 6.3 (3.4–11.1) |
Kidney urothelial carcinoma | 224 | 5.4 | 6.3 (3.8–10.2) |
Unknown primary undifferentiated neuroendocrine carcinoma | 674 | 2.7 | 6.1 (4.5–8.1) |
Duodenum adenocarcinoma | 249 | 3.6 | 6 (3.4–9.2) |